NBP — NovaBridge Biosciences
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1778016 ·
Last close
$1.38
Market Cap
$159.59M
52W High
$6.79
52W Low
$1.32
ADV30
507,877
Next earnings
2026-08-20
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 231,542,000 | 190,637,000 | 30,438,000 |
| Dec 2025 | 0 | — | -72,900,000 | -30,787,000 | 260,522,000 | 210,632,000 | 29,581,000 |
| Sep 2025 | 0 | — | -8,989,000 | -6,828,000 | 277,410,000 | 228,064,000 | 18,495,000 |
| Jun 2025 | 0 | — | -7,114,000 | -5,504,000 | 206,708,000 | 165,404,000 | 9,975,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,706,000
Investing CF
$-109,000
Financing CF
$57,725,000
CapEx
$-38,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.12
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,332,308,000
Inventory
—
Receivables
$1,793,000
ST Investments
$210,000
EBIT TTM
$-94,269,000
Pretax Income TTM
$-88,340,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -94,269,000 | -46,269,000 | 260,522,000 | 29,581,000 | 230,941,000 | -20,597,000 |
| Dec 2024 | 0 | -51,426,000 | -22,230,000 | 212,680,000 | 11,520,000 | 201,160,000 | -52,669,000 |
| Dec 2023 | 632,000 | -48,976,000 | -207,729,000 | 368,922,000 | 126,338,000 | 242,584,000 | -72,697,000 |
| Dec 2022 | -1,551,000 | -53,078,000 | -371,053,000 | 590,446,132 | 168,678,417 | 421,767,716 | -49,582,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $158.98M | $4.20 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $158.57M | $1.10 | — |
| ADCT | ADC Therapeutics SA | $162.14M | $1.27 | — |
| NERV | Minerva Neurosciences, Inc. | $162.34M | $3.40 | — |
| MENS | Jyong Biotech Ltd. | $150.69M | $2.03 | — |
News headlines (Yahoo Finance, 1h cache)
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
2026-09-08 11:00 · Yahoo
NovaBridge Biosciences to Participate in September Investor Conferences
2026-08-27 11:00 · Yahoo
NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ...
2026-08-20 21:02 · Yahoo
NovaBridge Biosciences Q2 2026 Earnings Call Summary
2026-08-20 12:30 · Yahoo
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
2026-08-20 11:00 · Yahoo
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
2026-08-13 21:00 · Yahoo
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
2026-07-24 21:00 · Yahoo
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
2026-06-29 11:00 · Yahoo
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
2026-06-16 11:00 · Yahoo
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth
2026-05-28 11:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.